Ikarian Capital’s RAPT Therapeutics RAPT Stock Holding History

Ikarian Capital’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-30,775	Closed	-$2.21M	–	149
2024 Q1	$2.21M	Buy	30,775 +23,425	+319%	+$3.26M	0.24%	84
2023 Q4	$1.46M	Buy	+7,350	New	+$910K	0.14%	92
2021 Q3	–	Sell	-43,750	Closed	-$11.1M	–	246
2021 Q2	$11.1M	Buy	+43,750	New	+$8.17M	0.9%	29
2021 Q1	–	Sell	-1,950	Closed	-$309K	–	329
2020 Q4	$309K	Hold	1,950	–	–	0.01%	204
2020 Q3	$503K	Buy	+1,950	New	+$433K	0.04%	142

Ikarian Capital's RAPT Position: Q1 2026 in Review

Ikarian Capital sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 665,271 shares — an estimated $22.5M sold.

Ikarian Capital first reported a position in RAPT in Q1 2024 and held it in 5 quarters. The position peaked at $22.5M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Ikarian Capital reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Ikarian Capital sold 665,271 RAPT Therapeutics shares in Q1 2026, an estimated $22.5M.
Ikarian Capital first reported a position in RAPT Therapeutics in Q1 2024 and held it in 5 quarters.
Ikarian Capital's RAPT Therapeutics position peaked at $22.5M in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.